Zürcher Nachrichten - European medicines watchdog rejects new Alzheimer's drug

EUR -
AED 3.832684
AFN 72.959602
ALL 98.462959
AMD 410.45402
ANG 1.873047
AOA 957.921829
ARS 1062.031565
AUD 1.668562
AWG 1.878277
AZN 1.784801
BAM 1.956057
BBD 2.098476
BDT 124.196346
BGN 1.95543
BHD 0.392152
BIF 3072.704402
BMD 1.043487
BND 1.411486
BOB 7.181945
BRL 6.350643
BSD 1.039337
BTN 88.357629
BWP 14.364891
BYN 3.401248
BYR 20452.35176
BZD 2.089175
CAD 1.498735
CDF 2994.808319
CHF 0.931781
CLF 0.03736
CLP 1030.865674
CNY 7.613704
CNH 7.60587
COP 4549.298739
CRC 524.369013
CUC 1.043487
CUP 27.652414
CVE 110.279514
CZK 25.108428
DJF 185.074358
DKK 7.458116
DOP 63.288329
DZD 140.667513
EGP 53.089373
ERN 15.65231
ETB 129.556951
FJD 2.417812
FKP 0.826423
GBP 0.829839
GEL 2.932642
GGP 0.826423
GHS 15.278011
GIP 0.826423
GMD 75.13081
GNF 8979.181761
GTQ 8.008054
GYD 217.438617
HKD 8.11073
HNL 26.382472
HRK 7.484837
HTG 135.967895
HUF 414.03543
IDR 16874.546735
ILS 3.801242
IMP 0.826423
INR 88.646863
IQD 1361.479186
IRR 43917.772492
ISK 145.170484
JEP 0.826423
JMD 162.611401
JOD 0.739936
JPY 163.242118
KES 134.177659
KGS 90.783029
KHR 4176.549681
KMF 486.395546
KPW 939.138018
KRW 1509.320727
KWD 0.321342
KYD 0.866114
KZT 545.821836
LAK 22747.993892
LBP 93069.24896
LKR 305.14016
LRD 188.634826
LSL 19.134218
LTL 3.081147
LVL 0.631195
LYD 5.106672
MAD 10.460077
MDL 19.14352
MGA 4903.645375
MKD 61.5431
MMK 3389.206159
MNT 3545.769827
MOP 8.320295
MRU 41.33344
MUR 49.25222
MVR 16.052761
MWK 1802.137182
MXN 20.931771
MYR 4.704048
MZN 66.682732
NAD 19.134218
NGN 1616.92545
NIO 38.245033
NOK 11.810924
NPR 141.372606
NZD 1.846749
OMR 0.401533
PAB 1.039337
PEN 3.870109
PGK 4.214555
PHP 61.430102
PKR 289.288974
PLN 4.258903
PYG 8104.066586
QAR 3.788799
RON 4.979106
RSD 117.045935
RUB 107.244587
RWF 1448.790677
SAR 3.91966
SBD 8.748133
SCR 14.551486
SDG 627.662417
SEK 11.505215
SGD 1.414024
SHP 0.826423
SLE 23.787187
SLL 21881.410825
SOS 593.978174
SRD 36.65877
STD 21598.081035
SVC 9.094197
SYP 2621.793487
SZL 19.129518
THB 35.780887
TJS 11.369896
TMT 3.662641
TND 3.311736
TOP 2.44395
TRY 36.710281
TTD 7.053928
TWD 34.050018
TZS 2468.324859
UAH 43.588037
UGX 3812.501768
USD 1.043487
UYU 46.356101
UZS 13399.76356
VES 53.713772
VND 26561.970104
VUV 123.884906
WST 2.882934
XAF 656.043343
XAG 0.035154
XAU 0.000398
XCD 2.820076
XDR 0.792804
XOF 656.043343
XPF 119.331742
YER 261.263155
ZAR 19.096059
ZMK 9392.640903
ZMW 28.762786
ZWL 336.002496
  • SCS

    -0.5800

    11.74

    -4.94%

  • NGG

    0.8200

    58.5

    +1.4%

  • RBGPF

    59.9600

    59.96

    +100%

  • BTI

    0.1131

    36.24

    +0.31%

  • RELX

    -0.3100

    45.47

    -0.68%

  • RIO

    -0.0900

    58.64

    -0.15%

  • CMSC

    0.0200

    23.86

    +0.08%

  • GSK

    0.1700

    33.6

    +0.51%

  • RYCEF

    -0.0100

    7.27

    -0.14%

  • BP

    0.1900

    28.6

    +0.66%

  • BCE

    0.0500

    23.16

    +0.22%

  • CMSD

    0.0000

    23.56

    0%

  • AZN

    0.9100

    65.35

    +1.39%

  • VOD

    0.0100

    8.39

    +0.12%

  • BCC

    -0.2600

    122.75

    -0.21%

  • JRI

    0.1100

    12.06

    +0.91%

European medicines watchdog rejects new Alzheimer's drug
European medicines watchdog rejects new Alzheimer's drug / Photo: Lex van LIESHOUT - ANP/AFP

European medicines watchdog rejects new Alzheimer's drug

Europe's medicines watchdog on Friday rejected a marketing request for a new Alzheimer's disease treatment, saying the risks of the medicine's side effects, including potential brain bleeding, outweighed the benefits.

Text size:

The decision by the Amsterdam-based European Medicines Agency was met with dismay, but experts said effective treatment for the degenerative mental disease affecting millions in Europe alone, was getting closer.

"The CHMP recommended not granting a marketing authorisation for Leqembi, a medicine intended for the treatment of Alzheimer's disease," the European Medicines Agency said, referring to its committee for evaluating drugs for human use.

Leqembi, which was developed by US multinational Biogen and Japanese-based Eisai, is the brand name of an active substance called lecanemab, which is used to treat adults with mild memory and cognitive problems resulting from the early stages of the common type of dementia.

But the CHMP said "the observed effect of Leqembi on delaying cognitive decline does not counterbalance the risk of serious side events associated with the medicine."

"The most important safety concern with Leqembi is the frequent occurrence of amyloid-related imaging abnormalities (ARIA), a side effect, seen in brain imaging, that involves swelling and potential bleedings in the brain," the EMA said.

- 'Unmet need' -

Leqembi is a monoclonal antibody, a type of protein that clings to a substance in the brain and can delay worsening of the disease. It is given intravenously every two weeks.

Leqembi, together with another Alzheimer's drug called Aduhelm -- also developed by Biogen and Eisai -- received approval from the US Food and Drug Administration (FDA) early last year.

Both drugs were approved through an accelerated process by the FDA for drugs treating serious conditions where there is an unmet medical need.

But in late January this year, Biogen pulled the controversial Aduhelm from the market, saying it was focusing on Leqembi instead.

Preliminary data from a trial of Leqembi was released in September 2022 and found it slowed cognitive decline in Alzheimer's patients by 27 percent.

Around eight million people in the European Union live with dementia, with Alzheimer's disease accounting for more than half of these cases, according to the Alzheimer Europe website.

Eisai, in a statement, said it was "extremely disappointed with the CHMP's negative opinion".

"There is a significant unmet need for new innovative treatment options that target an underlying cause of disease progression," Eisai's chief clinical officer Lynn Kramer said.

Eisai said it would seek a re-examination of the EMA's opinion "to ensure this treatment is available for eligible people living with early Alzheimer's disease in the EU as soon as possible."

The EMA said Eisai presented a main study involving 1,795 people with early Alzheimer's who either received Leqembi or a placebo, measured over a span of 18 months.

Eisai said that the watchdog added that its refusal had "no consequences for patients in clinical trials with Leqembi".

Eisai may now ask for a re-examination within 15 days, the EMA said.

- 'Ramp up efforts' -

Experts voiced disappointment at the EMA's refusal, but added there were "reasons to remain hopeful".

"Lecanemab has shown that it is possible to slow down disease progression, and research does work," said Tara Spires-Jones, president of the British Neuroscience Association.

"Now we need to ramp up our efforts to discover new and safer treatments," she said in a statement, adding that "each discovery brings us closer to new and better treatments."

Bart De Strooper, a professor in Alzheimer's disease at the University College London called the EMA's decision "unfortunate yet not unexpected".

"This conservative approach means that patients and doctors eager to explore a proven effective drug are now denied access," he said in a statement.

"With no current therapies available, it's disheartening to think that if we had applied such caution in the past, particularly with cancer drugs and their severe side effects, we might still be without cancer treatments today," De Strooper said.

A.P.Huber--NZN